# Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

> **NCT06703346** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **USWM CT, LLC** · enrollment: 87 (estimated)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Letetresgene autoleucel (Lete-Cel (GSK3377794))
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06703346
- **Lead sponsor:** USWM CT, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-31
- **Primary completion:** 2024-03-01
- **Final completion:** 2026-07-31
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703346, "Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06703346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*